Aidi Injection and Gefitinib in Lung Cancer Treatment
Author Information
Author(s): Zhang Jingyuan, Yang Siyun, Chen Xiaodong, Zhang Fanqin, Guo Siyu, Wu Chao, Wang Tieshan, Wang Haojia, Lu Shan, Qiao Chuanqi, Sheng Xiaoguang, Liu Shuqi, Zhang Xiaomeng, Luo Hua, Li Qinglin, Wu Jiarui
Primary Institution: Beijing University of Chinese Medicine
Hypothesis
Can Aidi injection enhance the effectiveness of gefitinib in treating gefitinib-resistant lung adenocarcinoma cells?
Conclusion
Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.
Supporting Evidence
- ADI treatment alone and combined with gefitinib significantly inhibited the proliferation, migration, and invasion of PC9GR cells.
- Whole-transcriptome sequencing revealed that PLAT is a key target for the increased efficacy of ADI combined with gefitinib.
- ADI downregulates the expression of PLAT, TNC, ITGB3, p-AKT, p-PI3K, and p-FAK.
Takeaway
Aidi injection helps fight a type of lung cancer that doesn't respond to a common drug by blocking cancer cell movement.
Methodology
In vitro and in vivo pharmacological experiments were conducted using PC9GR cells and NSG mice with PC9GR cell-derived tumors.
Participant Demographics
Male NSG mice, approximately 20g, aged 5-8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website